info@marketresearchfuture.com   📞 +1 (855) 661-4441(US)   📞 +44 1720 412 167(UK)   📞 +91 2269738890(APAC)

US Government Lays Out Certain Rules and Some Drugs for Negotiation Under Inflation Reduction Act

By Rahul Gotadki , 23 November, 2023

The United States has decided to cut the prices of certain medical drugs in 2023. It is due to the Inflation Reduction Act of 2022, recently signed by the government of the United States in 2022. The report includes specific provisions to lower the costs of drugs for people and the federal government.

Based on this act, Medicare can negotiate the prices of the prescribed drugs and lower the health care costs. This act allows Medicare to deal directly with companies to lower the prices of costly prescription drugs. The information from other sources mentioned that the drugs were taken from the 50 most pricey medications in Medicare Part D, an insurance plan for seniors who pay for the prescriptions. The data also revealed that the cost of Medicare was about USD 50 billion in total in 2022. According to the U.S. Department of Health and Human Services, with the help of the Centers for Medicare & Medicaid Services (CMS), the first ten drugs under Medicare Part D are to be negotiated. It added that the negotiations between Medicare and the participating companies will begin in 2023 and 2024. The negotiated prices will be implemented effectively in the market from 2026. According to government reports, people have paid USD 3.4 billion in 2022 for these drugs under negotiation. Ten drugs, such as Eliquis, Farxiga, Jardiance, Xarelto, Januvia, Entresto, Stelara, Imbruvica, Stelara, and Fiasp, are listed primarily under the negotiation process. The above drugs were priced at USD 50.5 billion, or about 20 percent of the total Part D drugs covered under the prescription for negotiations between June 2022 and May 2023.

There are various categories on which some drugs are not to be considered for the negotiation process. These drugs are all plasma-derived products, small biotech drugs, and FDA-approved drugs less than nine years from their license. Part D plans with higher expenditure costs on those expected to witness out-of-pocket cost savings from the news changes. Among the beneficiaries, those with expenditures above the disastrous threshold for conditions like hepatitis C, Cancer, etc., and other beneficiaries who benefit themselves from a brand with relatively high prices to cope with their medical conditions will be affected by these new changes on Part D negotiations. This decision by Medicare has affected the drugmakers as their stock prices have dropped after the decision. The producer companies are also expected to file lawsuits. However, the new finding from Medicare will benefit the senior citizens and the United States government in federal insurance plans.

Medicare Drug Price Negotiation Timeline for 2026 & 2027

.jpg

Latest News

2025.png
How Cobots are Replacing Conveyor Belts in SMEs Market 2025

In 2025, The “Cobots” Adoption in SMEs Market will Begin Transitioning as Small and Medium Sized Enterprises (SMEs) in Europe, Asia, and North America are cross-adopting collaborative robots (cobots) to enhance intralogistics and material handling…

Read More

IIoT-Startups-Secure-Record-Funding-in-Q2.jpg
IIoT Startups Secure Record Funding in Q2

The unprecedented funding of Industrial Internet of Things (IIoT) startups in Q2 marks a new record, indicating strong investors' confidence against the backdrop of an ongoing digital transformation. IIoT startups seem to be enjoying the animated…

Read More

How-Tesla-and-BMW-Slashed-Downtime-Using-Predictive-Maintenance.jpg
How Tesla and BMW Slashed Downtime Using Predictive Maintenance in 2025

By 2025, Tesla and BMW have adopted predictive maintenance as a way to optimize operations within the automotive industry. Both companies have established AI maintenance systems to address equipment failures which has greatly improved unplanned…

Read More

Overview.png
Africa Off-Grid Solar Solutions Rural Electrification Market Sees Surge in Investment and Innovation in 2025

In 2025, Africa is witnessing significant transformation in the off-grid solar drive rural electrification. With a fast-growing population, and steady expansion of commercial sectors, the demand for clean and affordable energy solutions has been…

Read More

India-MedTech-Market-in-2025.jpg
Policy Shifts and Economic Impact on India MedTech Market in 2025

The India MedTech market in 2025 is set for profound shifts owing to new regulations as well as the increased focus on domestic manufacturing. With the post-pandemic healthcare needs soaring, the government's policy spending in 2025 aims to turn…

Read More

Author Pic
Rahul Gotadki

Assistant Manager